Xbrane Biopharma: SEK240m directed issue with positive implications
11 juni, 08:25
11 juni, 08:25
Redeye comments on Xbrane following its SEK240m directed share issue targeting both institutional and industrial capital. The net proceeds bridge the funding gap, and we view this as a strong outcome among the possible financing scenarios - adjusting our base case accordingly.
11 juni, 08:25
Redeye comments on Xbrane following its SEK240m directed share issue targeting both institutional and industrial capital. The net proceeds bridge the funding gap, and we view this as a strong outcome among the possible financing scenarios - adjusting our base case accordingly.
Börsen idag
Börsen idag
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 493,49